Association between Folic Acid Supplementation and Hypertensive Disorder Complicating Pregnancy in Jiangsu Province: A Cross-Sectional Study

Author:

Cong Jing1,Pu Danhua1,Tan Rongrong1,Ge Xiaoyun2,Zhu Weipei3,Shen Cai-e4,Ge Jianfen5,Luo Xiucui6,Liu Juan7,Wu Jie1ORCID

Affiliation:

1. The State Key Laboratory of Reproductive Medicine, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, China

2. Nantong Maternal and Child Health Care Hospital, Nantong 226006, China

3. The Second Affiliated Hospital of Soochow University, Suzhou 215008, China

4. Suzhou Municipal Hospital, Suzhou 215008, China

5. Yancheng Maternity and Child Health Care Hospital, Yancheng 224001, China

6. Lianyungang Maternal and Child Heath Hospital, Lianyungang 222000, China

7. Yangzhou Maternal and Child Care Service Centre, Yangzhou 225000, China

Abstract

Objectives. To investigate the association of folic acid (FA) supplementation with hypertensive disorder complicating pregnancy (HDCP) and preeclampsia in Jiangsu Province, China. Materials and Methods. In this cross-sectional study, a total of 10,662 women with infants born between January 2017 and December 2018 were enrolled in Jiangsu Province, China. Maternal women with and without FA supplement intake were compared in this study. FA supplementation included 0.4 mg FA (0.4 FA), multivitamins with 0.4 mg FA (multivitamin (MV)+0.4 FA), and multivitamins with 0.8 mg FA (MV + 0.8 FA). Associations between FA intake, FA supplement dose or duration, (MV + FA) dosage per weight, and HDCP were analysed using ANOVA, the chi-square test, and logistic regression analysis. Results. Over the study follow-up period, the incidences of HDCP and preeclampsia were 3.5%, 1.4%, and 2.2%, 0.6% in the non-FA supplementation and FA supplementation groups, but only 1.5% and 0.1% in the MV + 0.8 FA group in early pregnancy. Compared with the non-FA group, HDCP and preeclampsia had the lowest risk in the MV + 0.8 FA group among the seven FA supplementation groups (HDCP: RR = 0.42, 95% CI = 0.27-0.68, P = 0.001 ; preeclampsia: RR = 0.09, 95% CI = 0.03–0.33, P = 0.001 ) in early pregnancy. Compared with the 0.4 FA alone group, the risk of HDCP and preeclampsia in women taking MV + 0.8 FA was significantly reduced (RR = 0.60, 95% CI = 0.41–0.87, P = 0.008 ; preeclampsia: RR = 0.18, 95% CI = 0.06–0.60, P = 0.005 ) in early pregnancy. (MV + FA)/BMI supplementation was associated with the risk of HDCP in early pregnancy ( P trend = 0.002). Conclusions. MV supplement with 0.8 mg FA during early pregnancy may be effective in reducing HDCP and preeclampsia risk. The study provided the viewpoint that (MV + FA)/BMI could be used as a reference for FA intake in pregnant women of different weights.

Funder

Maternal and Child Health Research Projects in Jiangsu Province

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3